Business Wire

POSIFLEX

16.1.2023 05:26:36 CET | Business Wire | Press release

Share
POSIFLEX Expands Success in POS with Superior Supply Chain Resilience

As one of the world’s top five electronic Point of Sale (POS) system suppliers, Posiflex Technology is wrapping up a particularly banner year for 2022, benefiting from vigorous refurbishments in retail and hospitality industries during the post COVID-19 pandemic era. With excellent supply chain management and risk control, Posiflex has been less affected by the global supply crisis resulted from COVID-19 lockdowns and geographical conflicts on top of other risk factors during 2022, and the company is eyeing toward a further leap in its global-leading position.

World’s 5th Ranked POS Supplier Rises to the Challenge

According to the latest survey conducted by market intelligence firm RBR, Posiflex ranks as the 5th biggest POS brand in terms of shipped units throughout 2021, with its strongest presence in Southeast Asia, the Middle East, Africa and Europe. The RBR survey also found that Posiflex rose to 1st place in countries like India, the Philippines, Saudi Arabia and Greece, with its market share in India as high as 54%, and Saudi Arabia 42%.

Why Customers Choose Posiflex: Customization Capability, Quality and Delivery

A new customer feedback analysis conducted by RBR has revealed that Posiflex customers on a worldwide base are most satisfied with the company’s professional support including customization service, reliable quality, and stable delivery (effective and efficient logistics), ranking as the top 3 Posiflex advantages in the eyes of customers.

  • Customization Service and better technical support

Posiflex is the only company among the top 5 POS suppliers to adopt a vertical integration strategy— it designs, manufactures, and sells POS systems and peripherals in-house, which means it is able to provide one-stop shopping service to customers as well as small volume customization to fit specific requirements of customers from different countries with various application scenarios and needs, including OS options, logo co-branding and special peripheral specs.

As Posiflex designs and manufactures products on its own, it is well-versed in technical details of its products and can be quicker and more helpful in responding to customers’ needs.

  • Reliable quality

To provide reliable products, Posiflex takes care in selecting quality materials and conducts comprehensive tests before shipment, including vibration test, drop test, plus the industry’s highest standard full-system loading test in 40°C burn-in chamber for 12+ hours for all shipping products. Customers’ feedback also shows high satisfaction with Posiflex’s product quality.

  • Good command of supply chain logistics

By merging various stages of production and supply chain into its own operations, Posiflex has also achieved better command of supply chain logistics with reduced need for outside entities. This, combined with a well-managed supplier network, has accumulated into better supply resilience for Posiflex to achieve more stable product deliveries and shorter delivery times than its competitors during the global supply shortage crisis in the past two years of the pandemic.

“Your success is our vision,” said Owen Chen, CEO of Posiflex, citing the company’s core values slogan. “We combine our technological advantages with customer needs and provide the most feasible products and services for partners and end users,” said Chen.

About POSIFLEX Group

Posiflex Group is a global leading Commercial Internet of Things (CIoT) enabler dedicated to providing O2O and embedded solutions. The group now is pillared by three business entities—Posiflex Technology, Portwell Inc. and US-based KIOSK Information Systems (KIS), specialized in the manufacturing of POS, embedded IPC and self-service kiosk respectively, with a common goal in pursuing a brave new world of smart commerce, where transactions become faster and more convenient physically or digitally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005378/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye